
News|Videos|November 19, 2026
AI Pulse Check: Annex 22 Favors Static Models
EU GMP Annex 22: AI Pulse Check panelists say most manufacturers aren’t ready, static AI models likely stay central, and local AI deployment grows.
Advertisement
Advertisement
Florin Muraru, an independent regulatory adviser specializing in EU and US regulatory strategy and AI governance, corrects a common assumption about the schedule. EU inspectors plan to send the final text to the European Commission by the end of the year, he explains, but that is not the date the annex will apply. EU GMP annexes typically take effect only after a transition period, so he advises against planning for an early-2027 effective date.
Related to this article

Cole and Jaenisch explain where pharma should keep manual checks, how to vet AI skills in hires, and why self-taught AI risks GMP.

Cole and Jaenisch explain why defending against AI poisoning in pharma manufacturing calls for a data steward role, immutable instruction ledgers, and automation.

Regulators will test pharma companies against their own internal AI policies. Jaenisch, Muraru, and Pandey explain how to build defensible, inspection-ready AI practices.

Panelists on the PharmTech AI Pulse Check weigh a December AI playbook, EMA/MHRA moves, PCCP accountability gaps, and MCP-ready regulatory guidance.

No operator touches a CAR-T batch before demonstrating proficiency. Generative AI users should meet the same standard, and a higher one, because an AI error does not stay inside one batch.

The PharmTech AI Pulse Check panel discusses why MHRA and FDA oversight of pharma AI continues past go-live, and who validates the regulators' own AI.

How confident is the bio/pharma workforce heading into 2027? PharmTech wants to find out, and we need your input.
Advertisement
Advertisement

